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Monoclonal antibodies for copper-64 PET
dosimetry and radioimmunotherapy
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Background: We previously described a two-antibody model of 64Cu radioimmunotherapy to evaluate low-dose, solidtumor response. This model was designed to test the hypothesis that cellular internalization is critical in causing tumor
cell death by mechanisms in addition to radiation damage. The purpose of the present study was to estimate radiation
dosimetry for both antibodies (mAbs) using positron emission tomography (PET) imaging and evaluate the effect of
internalization on tumor growth.
Results: Dosimetry was similar between therapy groups. Median time to tumor progression to 1 g ranged from 7–12
days for control groups and was 32 days for both treatment groups (p < 0.0001). No statistically significant difference
existed between any control group or between the treatment groups.
Material and Methods: In female nude mice bearing LS174T colon carcinoma xenografts, tumor dosimetry was calculated using serial PET images of three mice in each group of either internalizing 64Cu-labeled DOTA-cBR96 (DOTA =
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) or non-internalizing 64Cu-labeled DOTA-cT84.66 from 3 to 48 h.
For the therapy study, controls (n = 10) received saline, DOTA-cBR96 or DOTA-cT84.66. Treatment animals (n = 9) received
0.890 mCi of 64Cu-labeled DOTA-cBR96 or 0.710 mCi of 64Cu-labeled DOTA-cT84.66. Tumors were measured daily.
Conclusions: PET imaging allows the use of 64Cu for pre-therapy calculation of tumor dosimetry. In spite of highly
similar tumor dosimetry, an internalizing antibody did not improve the outcome of 64Cu radioimmunotherapy. Radioresistance of this tumor cell line and copper efflux may have confounded the study. Further investigations of the therapeutic efficacy of 64Cu-labeled mAbs will focus on interaction between 64Cu and tumor suppressor genes and copper
chaperones.
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Cu-TETA-Tyr3-octreotate in the highly aggressive CA20948
rat pancreatic tumor model at a low tumor absorbed dose.2
Evaluation of intracellular distribution of 64Cu offers some
potential insight into additional cytotoxicity mechanisms. In
vivo distribution studies in rats of 64Cu-TETA-octreotide demonstrated transchelation of 64Cu to superoxide dismutase (SOD) in
the liver.3 Other experiments identified 64Cu from 64Cu-TETAoctreotide in the nucleus (19.5%) and mitochondria (21.1%) of
AR42J rat pancreatic tumor cells in vitro over a 24 h period.4 As
there was no evidence that the somatostatin analogue itself had
accumulated in these locations, it is possible that 64Cu transchelates to copper cofactor enzymes, metalloproteins and copperhandling chaperones following internalization.
We previously reported the development and characterization of a two-antibody model for comparison of 64Cu RIT.5 We
confirmed the internalization of the mAb cBR96 which recognizes the Lewisy ceramide variant present in multiple human
and veterinary carcinomas.6,7 We also confirmed that the mAb
64

Copper-64 is a radionuclide produced by a cyclotron with an
intermediate half-life (T1/2 = 12.7 h) that decays by both β+ (655
keV, 17.4%) and β- (573 keV, 39.0%) emission, making it suitable
for labeling monoclonal antibodies (mAbs) for positron emission
tomography (PET) imaging and radioimmunotherapy (RIT) of
cancer. Previous experiments in xenograft-bearing rodent models have demonstrated tumor cytotoxicity of internalizing 64Cu
radiopharmaceuticals superior to other nuclides, but at much
lower tumor absorbed doses.
Two studies in particular offer tantalizing evidence of cytotoxicity in addition to traditional radiation damage mechanisms.
Connett and others reported 82% complete tumor responses
to the 64Cu-labeled mAb 1A3 in Golden Syrian hamsters bearing GW39 xenografts, at a tumor absorbed dose of only 586
rad (5.86 Gy).1 Lewis and others reported complete, but temporary, tumor remissions using the somatostatin analogue
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tumor response to an internalizing versus a noninternalizing mAb at the calculated tumor absorbed
dose of 10 Gy in a mouse xenograft model of cancer.
Results
PET/CT imaging. Representative PET/CT images
for both 64Cu-labeled mAbs at time points from
3–48 h are shown in Figure 1. Tumor uptake was
heterogeneous in most studies at the 24 and 48 h time
points (Fig. 2). Tumor uptake of 64Cu-DOTA-cBR96
was 5.06% ID/organ at 3 h, 12.38% ID/organ at
26 h and 16.12% ID/organ at 48 h. Tumor uptake
for 64Cu-DOTA-cT84.66 was 7.25% ID/organ at 3 h,
17.45% ID/organ at 25 h and 20.24% ID/organ at
49 h. There were no statistically significant differences
between conjugates at any time point, although the
power of the test is limited due to the small numbers
of mice that could be imaged daily. This pattern of
uptake was different from that seen in the traditional
biodistribution studies in which tumor accumulation
of 64Cu-DOTA-cBR96 was significantly more rapid
at 3 h than that of 64Cu-DOTA-cT84.66. Using a
Monte Carlo N-particle Transport Code,12 the calculated absorbed dose to the tumors was 484 rad/mCi
(131 mGy/MBq) for 64Cu-DOTA-cBR96 and 643
rad/mCi (174 mGy/MBq) for 64Cu-DOTA-cT84.66.
Qualitative analysis of the PET images revealed
few regions of radioactivity accumulation that were
not predicted by the traditional biodistribution studies. What did appear unexpectedly in the 3 h images
for 64Cu-DOTA-cBR96 was radioactivity associated with the vascular bed of the tail base. A lesser
accumulation of radioactivity was visible in the tail
Figure 1. Representative PET/CT fusion scans at time points of approximately 3,
of mice receiving 64Cu-DOTA-cT84.66, likely associ64
64
24 and 48 h. The Cu-DOTA-cBR96 mice are presented above, and the Cu-DOTAated with small, perivascular leakage at the injection
cT84.66 mice are presented below. Note the subtle, but important, differences in the
site. This radioactivity largely washed out in both
patterns of distribution to the tumor and normal organs for each mouse imaged over
a 2 day period. Much more activity is visible in the tail base region for all 64Cu-DOTAcases over the subsequent 48 h period. Minor intesticBR96 conjugates. Increased liver and intestine activity from biliary excretion is
nal uptake was visible in the 48 h scan of mice receivvisible with 64Cu-DOTA-T84.66, particularly in (C).
ing 64Cu-DOTA-cBR96. As with the traditional
biodistribution studies,5 the hepatic radioactivity of
64
Cu-DOTA-cT84.66 was clearly greater than that of
cT84.66,8 which recognizes carcinoembryonic antigen (CEA) 64Cu-DOTA-cBR96. This was best illustrated by the 48 h images
is non-internalizing.5 This antigen is also present on numerous depicted in Figure 1C. Intestinal radioactivity was clearly visible
human carcinomas8 and reported in veterinary hepatocellular in mice imaged with 64Cu-DOTA-cT84.66 at 48 h.
carcinomas, rete testis mucinous adenocarcinomas and choroid
Therapy study. The growth curves of the tumors are presented
plexus carcinomas.9-11 The biodistributions of these antibodies in Figure 3. Aggressive, unrestricted tumor growth was evident
were characterized in an LS174T nude mouse model of colon for the three control groups. Both experimental groups displayed
cancer and tumor dosimetry was estimated.5
a tumor growth delay, followed by unrestricted tumor growth.
The purpose of these experiments was to test the hypothesis Abrupt decline in tumor volume was recorded for 22 of the 48
that internalization of 64Cu is the single necessary step in caus- mice in the study. This decrease represented sudden ulceration
ing low-dose cytotoxicity with RIT of cancer. An imaging study and collapse of the tumor. The majority of these events occurred
was performed to test the hypothesis that the actual tumor dose when tumor masses reached 1 g or larger. Mice were sacrificed
received from the therapeutic administration would be equiva- when the tumor mass reached 3 g, the tumor developed severe
lent between the two 64Cu-labeled mAbs. A RIT experiment ulceration or the tumor impaired the ability of the mouse to
was performed to test our overarching hypothesis by comparing ambulate. Because of the tendency to ulcerate at a tumor burden
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over 1 g, the most meaningful end point was the time to progression of tumor mass to 1 g. The Kaplan-Meier curve describing
time to progression is presented in Figure 4. The median time
to progression to 1 g ranged from 7–12 days for the three control
populations. The median time to progression to 1 g was 32 days
for both of the experimental groups. There was no statistically
significant difference between the medians among the control
groups of saline and unlabeled antibodies. The two experimental
groups were also statistically indistinguishable; however, there
was a statistically significant difference between the experimental
and control groups (p = 0.0001). There was no evidence of toxicity in any of the mice in the experimental groups or the control
groups receiving unlabeled mAbs.
Discussion
This therapy study yielded mixed results, some expected and
some surprising. As hypothesized it is clear from the similarity
between the saline control and the unlabeled DOTA-cBR96 and
DOTA-cT84.66 groups that the mAbs did not initiate antibodydependent cellular cytotoxicity (ADCC) in these animals. There
was no significant difference between the times to progression to
1 g tumor mass, and no growth delay was observed in the mice
receiving unlabeled antibodies compared to the mice receiving
saline. Although an in vitro study previously demonstrated evidence for direct cytotoxicity as well as ADCC by unmodified
BR96,7 to our knowledge there are no in vivo experiments that
confirm this effect. The lack of direct cytotoxicity or ADCC in
this study may be due to ambient concentrations below those
which would be optimal for cell killing or potentially due to
interference with this mechanism by DOTA conjugation. In
either case antibody-induced immune response did not affect the
outcome of this therapy study.
What was unexpected was the lack of support for the
hypothesis that internalization is the single critical step in the
unusual cytotoxicity previously demonstrated for internalizing
64
Cu-labeled radiopharmaceuticals. Our in vitro studies confirmed the internalizing property of 64Cu-DOTA-cBR96 and the
non-internalizing properties of 64Cu-DOTA-cT84.66.5 However,
the 64Cu efflux studies previously published offer the possibility that a lack of persistence of 64Cu within the cells to interact
with copper chaperones after internalization may explain the lack
of differential therapeutic efficacy between these two mAbs.5
Cellular efflux has not been evaluated for 64Cu- and 131I-labeled
1A3 in GW39 cells, used in the experiment in which 64Cu-BAT2IT-1A3 exhibited markedly superior tumor responses (Anderson
CJ, personal communication). Rapid efflux of internalized 64Cu
is a tempting explanation for the results of these experiments, but
remains speculative as cellular efflux is difficult to quantify in
vivo. What is likely, however, is that the trafficking of 64Cu into
the nucleus and mitochondria previously described in reference 4,
would cause accumulation, and thus residualization, of radioactivity within the cells. Recently, trafficking of 64Cu to the nucleus
has been associated with the expression of wild-type p53.13 The
LS174T cell line expresses wild-type p53, but did not show evidence of residualization.14 It is possible that chelation with a more
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Figure 2. Representative two-dimensional slices through the tumor
region for one mouse each from the 64Cu-DOTA-cBR96 (left) and 64CuDOTA-cT84.66 (right) treatment groups at 24 h. The plane depicted in
the PET/CT image denotes the origin of the two-dimensional transaxial
slice. The ellipse depicted denotes the region of interest of the tumor,
but is not equivalent to the very precise ROI drawn around the tumor
regions for PET dosimetry calculation.

stable ligand would have resulted in more favorable intracellular
trafficking. Boswell and others have described a cross-bridged
cyclam with greater stability than traditional chelators such as
DOTA.15 Similarly, a bombesin peptide labeled with 64Cu using
the chelator NOTA (NOTA = 1,4,7-triaazacyclononane-1,4,7triacetic acid) demonstrated greater in vivo stability than a similar peptide conjugated with DOTA.16 However, intranuclear
accumulation has been reported to be inhibited by more stable
chelation in at least one model.17
The large difference in mAb dose between the biodistribution
and therapy studies prompted us to confirm the tumor dosimetry by PET imaging studies. In the biodistribution experiments,
different groups of mice were sacrificed at each time point. As
such, mice exhibiting unusual clearance properties would be
randomly distributed throughout the pool of animals, thwarting
a systematic understanding of the pattern of microscopic antibody metabolism in the tumor. Furthermore, the injected dose
of radiation and mAb in the biodistribution studies was nearly
one log below the therapeutic dose, leaving open the possibility
that a larger dose of antibody might be distributed differently.
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Figure 3. (A–E) Tumor growth curves for each control and experimental group. Tumor volumes are expressed in mm3 and time is in days from treatment, after 14 days of tumor growth. Plot (A) represents the saline control mice. Plot (B) represents the unlabeled DOTA-cBR96 control mice.
Plot (C) represents the unlabeled DOTA-cT84.66 control mice. Plot (D) are the 64Cu-DOTA-cBR96 experimental mice. Plot (E) are the 64Cu-DOTA-cT84.66
experimental mice. Large decreases in tumor volume were due to ulceration and necrosis of those tumors.

A more ideal dosimetry study would follow the distribution of
the 64Cu-labeled mAbs in the same group of living mice over
a 48 h period. This experiment would allow a more complete
understanding of the progression of distribution of the mAbs
and 64Cu within the animals. An animal that cleared antibody or
radioactivity rapidly in the reticuloendothelial system would be
identified and accounted for in the modeling of the subsequent
therapy experiment. The ability to image the distribution of the
64
Cu-labeled mAbs with PET permits this quantification of biodistribution, including tumor targeting. Minor limitations exist
in the ability to quantify the radioactivity within a region of
the PET scan. However, because of the small size of the mouse,
the energy of the annihilation photons detected (511 keV), as
well as the subcutaneous location of the tumors, factors such

1004

as attenuation were likely to introduce negligible error into the
calculations.
As previously discussed, the low abundance of β+ emission
from 64Cu decay allows for efficient imaging of therapeutic
doses of the radiolabeled mAbs. Thus, a full therapy dose, rather
than a tracer dose, may be administered to observe biodistribution under conditions of greater mAb concentration relative
to antigen pool. Qualitative evaluation of the imaging studies
detected little distribution to tissue that was not predicted by the
results of the sacrificial studies. However, endothelial binding
of 64Cu-DOTA-cBR96 in the tail vasculature was unexpected.
In retrospect, this uptake may have been masked in the traditional biodistribution data because the tail was counted with the
caudal half of the carcass. As with the circulating CEA pool
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for 64Cu-DOTA-cT84.66, the endothelial sink for deposition of
radioactivity may account for the delayed tumor accumulation
of 64Cu-DOTA-cBR96, as detected by PET imaging, relative to
the traditional biodistribution analysis.5 Vascular endothelial
binding did not appear to diminish total tumor uptake, and
the tumor distribution remained similar between the two mAbs
at 24 and 48 h post-injection. Minor intestinal activity was
observed in mice treated with 64Cu-DOTA-cBR96. Intestinal
cross-reactivity with cBR96 has not been previously reported in
mice.7 It has, however, been identified in the large intestine of
dogs.6 It is not surprising that some cross-reactivity with normal tissue would exist. Consistent with sacrificial biodistribution results, 64Cu-DOTA-cT84.66 demonstrated increased liver
and spleen activity over time, and intestinal activity became visible at 48 h as biliary excretion of 64Cu occurred. In the case of
either mAb, it must be considered that copper could have been
excreted into the intestinal tract unbound to antibody through
the normal copper processing function of the liver. This series
of non-invasive imaging studies gave striking confirmation of
the biodistributions previously determined by more traditional
means, with the added accuracy of repeated measures in the
same living mice, and the potential to use fewer animals to
obtain equivalent results.
The most valuable information gained from these images,
however, was to estimate tumor dosimetry based on region of
interest (ROI) evaluation. Because 64Cu was only available on
a bi-monthly basis at the time, tumors were implanted 14 days
prior to the experiment. During this time, tumors were expected
to grow to approximately 200 mg in size. Prior to the imaging studies tumor growth was greater than expected, reaching
800–900 mg, four times the size of the tumors in the traditional
biodistribution studies. On the two-dimensional PET images
(Fig. 2), the tumors displayed heterogeneity of dose distribution
within the parenchyma in most cases, suggesting that the large
tumors had developed hypovascularized and likely necrotic areas
within the tumors. Including the entire tumor area within the
ROI, the larger tumors accumulated twice the radioactivity that
was measured in the initial biodistribution studies. However,
with four times the volume, the resulting dose to the tumors was
approximately half that calculated previously. The therapy mice
were injected with radiation calculated to deliver the same dose
(10 Gy) to a 200 mg tumor, regardless of the mAb administered.
Correcting for injected activity, for 0.89 mCi of 64Cu-DOTAcBR96, the actual dose to the tumor was 4.31 Gy, and for 0.71
mCi of 64Cu-DOTA-cT84.66, the dose was 4.56 Gy in the larger
tumors in the PET dosimetry experiment. Within 5% of each
other, these doses are remarkably similar, given the potential for
individual mouse variability, the limitations of sacrificial studies, and the great disparity in tumor size between the traditional
biodistribution studies and PET imaging. Although not representative of the absolute dose administered in the therapy study,
this result confirms that the dosimetry would have been similar
between experimental groups in the therapy study.
PET dosimetry offers great advantages for future 64Cu therapy studies. Preliminary dose-finding biodistribution studies can
be accomplished using far fewer mice, and allowing statistical

Figure 4. Kaplan-Meier plot of time to progression of tumor mass to 1 g.
There was no statistically significant difference between control groups
or between groups receiving 64Cu. There was a significant difference
between control groups and those receiving 64Cu (p < 0.0001).

evaluation with repeated measures to give greater power to the
analysis. When therapy studies are performed, individual mice
could be screened with a tracer dose and therapeutic mass, in order
to compare biodistributions, metabolism and tumor uptakes.
From this test dose, the appropriate dose to deliver the desired
tumor absorbed dose could be calculated, ensuring that all mice
receive the intended dose. These mice could then be imaged again
after the therapy dose to confirm expected distributions. Using this
method, future therapy studies of 64Cu-labeled delivery platforms
could be better controlled, yielding more meaningful results.
In the case of this therapy study, the results of the imaging
analysis suggested that the mice did, indeed, receive equivalent
tumor absorbed doses from 64Cu-labeled mAbs. This lends further support to the veracity of the outcome, suggesting that the
hypothesis tested cannot be supported by this two-antibody
system and tumor model. Although internalization appeared
in previous studies to be necessary for the enhanced cytotoxicity of 64Cu-labeled radiopharmaceuticals, the new information
reported here suggests that cellular characteristics of copper
handling or activity of apoptotic pathways may also play a large
role in the cytotoxic mechanism. In vitro, LS174T cells clearly
expressed mechanisms by which 64Cu from both mAbs was
removed from the cell into the extracellular matrix. This would
be expected for a non-internalizing mAb like cT84.66, as CEA
is shed continuously, but internalization of cBR96 should have
resulted in residualization of radioactivity within the cell. Future
evaluation of these agents must continue to focus on the fate of
64
Cu within the target cell.
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Material and Methods
Cell line. The LS174T cell line was obtained from the American
Type Culture Collection (Manassas, VA). Immediately prior
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to implantation into nude mice, the cells were tested for mycoplasma and screened for a panel of 13 murine pathogens by PCR.
All test results were negative, and all sentinel mice in the facility
housing the nude mice tested negative for these pathogens during
the course of the studies.
Animal model. The imaging and therapy studies were conducted in compliance with a protocol approved by the Animal
Care and Use Committee of the University of MissouriColumbia Animal Care Quality Assurance Office. Outbred
female nu/nu mice (4–6 weeks of age) were obtained from
Harlan Sprague Dawley (Indianapolis, IN). Mice were injected
subcutaneously with 0.15 mL of Hank’s Balanced Salt Solution
containing 2 x 106 LS174T colon tumor cells in the right prefemoral region via a 23 gauge needle. Tumors for the imaging
study reached a mean weight of 863 mg in 14 days. Tumors for
the therapy study reached a mean weight of 171 mg in 14 days.
Monoclonal antibodies. The methods used to prepare the
conjugates and perform quality control evaluation have been
previously described in reference 5. Briefly, the antibodies used
in these experiments were conjugated at a 10:1 molar ratio of
DOTA-OSSu:mAb for the human/murine chimeric antibody
cBR96 and a 20:1 molar ratio of DOTA-OSSu:mAb for the
human/murine chimeric antibody cT84.66. The conjugates
were purified by extensive dialysis against 0.1 M ammonium
citrate buffer, pH 5.5. These conjugation ratios yielded 1.26
functional chelates per cBR96 mAb and 3.6 functional chelates per cT84.66 mAb.5 Immunoreactivity and serum stability were quantitative by ELISA methods for DOTA-cBR96,5
and by reaction with purified antigen and SE-HPLC for
DOTA-cT84.66.8
Antibody labeling. Copper-64 was produced on a biomedical
cyclotron at Washington University School of Medicine by previously published methods.18 Conjugates were labeled with 64Cu
to a specific activity of 10 μCi/μg in 0.1 M ammonium citrate,
pH 5.5, for 1 h at 43°C.19 Diethylenetriaminepentaacetic acid
(DTPA) was then added to a final concentration of 1 mM, and the
reaction mixtures were let stand for 15 min at room temperature.
The labeled mAbs were purified and exchanged into phosphatebuffered saline by gel-filtration spin column chromatography,
using Bio-Spin 6 columns (Bio-Rad, Hercules, CA).19 Specific
activity of labeling was determined prior to purification and radiochemical purity was determined after purification, by SE-HPLC
using a Waters (Milford, MA) Delta 600 chromatograph
equipped with a manual Rheodyne injector, a Waters 2487 dual
wavelength UV detector, a Packard (Downers Grove, IL) 500TR
Flow Scintillation Analyzer with a GAMMA-C flow cell for 64Cu,
a Waters busSAT/IN analog-digital interface, and the Waters
Millennium 32 software package. A Phenomenex (Torrance, CA)
BioSep-SEC-S 3000 column (7.8 x 300 mm, 5 μm, 290 Å), an
isocratic mobile phase of 100 mM NaH2PO4/0.05% NaN3, pH
6.8 and a flow rate of 1.0 mL/min were used.
PET imaging. Fourteen days prior to the start of the study,
six outbred female nu/nu mice were inoculated with LS174T
cells as described above. Mice were divided into two groups
(n = 3). Based on previously reported data in reference 5, respective groups received either 0.89 mCi of 64Cu-DOTA-cBR96 or

0.71 mCi of 64Cu-DOTA-cT84.66 intravenously via the tail vein
on day 1 of the study. Mice were anesthetized with isoflurane in a
Plexiglas imaging chamber and lightly immobilized with gauze.
PET imaging was performed using a Philips MOSAIC high
resolution rodent PET scanner and CT imaging was performed
using an ImTek microCAT II scanner. Each mouse was imaged
for 15–60 min by PET and for 8 min by CT at 3, 24 and 48 h
post-injection.
PET tumor dosimetry. High resolution imaging data was
processed using the Philips Syntegra image fusion software for
co-registration of anatomic (CT) and molecular (PET) imaging.
Following previously published protocols,20,21 a region of interest (ROI) was drawn around the complete area of the tumor,
and the total number of counts/pixel/min was calculated. The
total counts within the tumor area were compared to the total
counts within a known standard dose of 64Cu for each mAb to
calculate the percent injected dose to each tumor (% ID/organ)
at each time point, from which the doses of radiation delivered
to the tumors over the imaging period were estimated in rad/
mCi and mGy/MBq. Total absorbed dose was assumed to be
averaged within the tumor without attempt to separate high and
low-uptake regions of the tumors. The imaging results were also
evaluated subjectively for distribution of radioactivity within soft
tissues of the mouse body.
Therapy study. Fourteen days prior to the start of the study,
outbred female nu/nu mice were inoculated with LS174T cells
as described above. Mice were divided into three control groups
(n = 10) and two experimental groups (n = 9). Control groups
received either 0.15 of mL saline, 0.089 mg of unlabeled DOTAcBR96 or 0.071 mg of unlabeled DOTA-cT84.66, respectively, administered intravenously via the tail vein on day 1 of
the study. A control group of 64Cu-DOTA was not included,
as an anticipated low calculated radiation dose would not be
expected to be therapeutic if not targeted to the tumor and
excretion would likely be extremely rapid. Experimental groups
received either 0.89 mCi of 64Cu-DOTA-cBR96 or 0.71 mCi of
64
Cu-DOTA-cT84.66 intravenously via the tail vein on day 1 of
the study. Mice were weighed daily and examined for signs of
overt systemic toxicity (e.g., weight loss >20%, lethargy, diarrhea, cyanosis). Tumors were measured in three dimensions and
tumor volume calculated by the formula length x width x depth
x π/6 daily until tumor growth stabilized, then three times
weekly. Mice were observed for adverse reactions on a twice
daily basis. Mice were sacrificed if their tumor reached 3 g, body
weight decreased >20%, the tumor ulcerated or the tumor interfered with normal ambulation.
Statistical analysis. Comparison of groups in the therapy
study was accomplished using a Kaplan-Meier log-rank analysis.
Comparison of % ID/organ values was accomplished using oneway analysis of variance (ANOVA). Differences were deemed significant at the 95% confidence level (p ≤ 0.05).
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